Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Cepheid CPHD NASDAQ

NASDAQ • Healthcare • Biotechnology • USD

SharesGrow Score
30/100
0/5 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

Cepheid (CPHD) is a Biotechnology company in the Healthcare sector, currently trading at $52.95. It has a SharesGrow Score of 28/100, indicating a weak investment profile with 0 out of 7 criteria passed.

Financials: revenue is $539M, +17.6%/yr average growth. Net income is $49M (loss), growing at -55.2%/yr. Net profit margin is -9% (negative). Gross margin is 49.9% (-3.8 pp trend).

Balance sheet: total debt is $315M against $370M equity (Debt-to-Equity (D/E) ratio 0.85, moderate). Current ratio is 3.91 (strong liquidity). Debt-to-assets is 38.4%. Total assets: $822M.

SharesGrow 7-Criteria breakdown: Value ?/100 (Fail), Growth 48/100 (Partial), Past 0/100 (Fail), Health 50/100 (Partial), Moat 42/100 (Fail), Future ?/100 (Fail), Income 10/100 (Fail).

CPHD SharesGrow Score Overview

38/100
SharesGrow Score
Below average — proceed with caution
View full scorecard →
VALUE 0/100
Valuation — P/E, PEG, Forward PEG
GROWTH 48/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 50/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 42/100
Gross margin is + market cap
FUTURE 0/100
Analyst outlook — as buy
INCOME 10/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — CPHD

—
VALUE N/A
N/A
No analyst coverage available for this stock.
~
GROWTH Partial
48/100
CPHD: +17.6%/yr revenue is, -55.2%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
~
HEALTH Partial
50/100
Balance sheet CPHD: Debt-to-Equity (D/E) ratio 0.85 (moderate), Current ratio is 3.91 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
42/100
CPHD: Gross margin is 49.9% (-3.8 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 42/100. ≥ 70 = Pass.
View details →
—
FUTURE N/A
N/A
No analyst coverage available for this stock.
✗
INCOME Fail
10/100
CPHD: Net profit margin is -9%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.
View details →

Stock Chart & Stats

Market Data
52-Week Range53.91-25.09
Volume2.65M
Avg Volume (30D)1.17M
Beta (1Y)0.62
Share Statistics
EPS (TTM)-0.67
Shares Outstanding$71.93M
IPO Date2000-06-22
Financial Highlights & Ratios
Revenue (TTM)$538.58M
Gross Profit$268.71M
EBITDA$11.17M
Net Income$-48.53M
Operating Income$-30.86M
Total Cash$322.72M
Total Debt$315.31M
Net Debt$202.75M
Total Assets$821.65M
Price / Earnings (P/E)-79
Analyst Forecast
Company Info
ExchangeNASDAQ
CurrencyUSD

Price Chart

Track all markets on TradingView
CPHD
Cepheid  ·  NASDAQ
Healthcare • Biotechnology

People Also View

LLY
LLY
Eli Lilly and Company
$922.50
-0.76%
 JNJ
JNJ
Johnson & Johnson
$240.10
+0.90%
 ABBV
ABBV
AbbVie Inc.
$210.32
+1.86%
 RHHBF
RHHBF
Roche Holding AG
$418.50
+1.82%
 RHHBY
RHHBY
Roche Holding AG
$51.02
+0.65%
 AZN
AZN
AstraZeneca PLC
$204.38
+1.06%
 NVSEF
NVSEF
Novartis AG
$156.48
+0.00%
 MRK
MRK
Merck & Co., Inc.
$119.96
-0.16%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message